615 related articles for article (PubMed ID: 11689580)
41. Once-weekly dose of epoetinum alfa in cancer patients with anemia receiving radiotherapy.
Ots PM; Pérez AR; Carrizosa CL; Ocaña CV; de Dios Sáez Garrido J; Delgado Pérez JM
Clin Transl Oncol; 2005 Dec; 7(11):486-92. PubMed ID: 16373059
[TBL] [Abstract][Full Text] [Related]
42. Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life.
Cortesi E; Gascón P; Henry D; Littlewood T; Milroy R; Pronzato P; Reinhardt U; Shasha D; Thatcher N; Wilkinson P
Oncology; 2005; 68 Suppl 1():22-32. PubMed ID: 15855813
[TBL] [Abstract][Full Text] [Related]
43. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
Case AS; Rocconi RP; Kilgore LC; Barnes MN
Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
[TBL] [Abstract][Full Text] [Related]
44. A multicenter study of recombinant human erythropoietin (epoetin alpha) in the management of anemia in cancer patients receiving chemotherapy.
Pawlicki M; Jassem J; Bösze P; Lotan C; Kurteva GP; Siddiqui M; Kosmidis PA; Rigatos GA; Kansu E; Durkovic P; Aziz Z; Al Idrissi H; Roth A; Cozma G
Anticancer Drugs; 1997 Nov; 8(10):949-57. PubMed ID: 9436638
[TBL] [Abstract][Full Text] [Related]
45. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy.
Crawford J; Robert F; Perry MC; Belani C; Williams D;
J Thorac Oncol; 2007 Mar; 2(3):210-20. PubMed ID: 17410044
[TBL] [Abstract][Full Text] [Related]
46. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.
Afdhal NH; Dieterich DT; Pockros PJ; Schiff ER; Shiffman ML; Sulkowski MS; Wright T; Younossi Z; Goon BL; Tang KL; Bowers PJ;
Gastroenterology; 2004 May; 126(5):1302-11. PubMed ID: 15131791
[TBL] [Abstract][Full Text] [Related]
47. Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience.
Quirt I; Kovacs M; Couture F; Turner AR; Noble M; Burkes R; Dolan S; Plante RK; Lau CY; Chang J
Oncologist; 2006 Jan; 11(1):73-82. PubMed ID: 16401716
[TBL] [Abstract][Full Text] [Related]
48. Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy.
Chu E; Einhorn LH; Lefebvre P
J Support Oncol; 2006 May; 4(5):243-50. PubMed ID: 16724648
[TBL] [Abstract][Full Text] [Related]
49. Use of erythropoietin-stimulating agents in breast cancer patients: a risk review.
Crouch Z; DeSantis ER
Am J Health Syst Pharm; 2009 Jul; 66(13):1180-5. PubMed ID: 19535656
[TBL] [Abstract][Full Text] [Related]
50. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
Ariganello O; Mancuso A; Di Molfetta M; Diana F; Beccaglia P; Cortesi E; De Marinis F
Lung Cancer; 2004 Oct; 46(1):119-24. PubMed ID: 15364140
[TBL] [Abstract][Full Text] [Related]
51. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
Thanakitcharu P; Siriwiwatanakul N
J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
[TBL] [Abstract][Full Text] [Related]
52. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
[TBL] [Abstract][Full Text] [Related]
53. Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.
Biesma B; van de Werf PR; Melissant CF; Brok RG
Lung Cancer; 2007 Oct; 58(1):104-11. PubMed ID: 17601632
[TBL] [Abstract][Full Text] [Related]
54. Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial.
Wilkinson PM; Antonopoulos M; Lahousen M; Lind M; Kosmidis P;
Br J Cancer; 2006 Apr; 94(7):947-54. PubMed ID: 16570051
[TBL] [Abstract][Full Text] [Related]
55. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management.
Couture F; Turner AR; Melosky B; Xiu L; Plante RK; Lau CY; Quirt I
Oncologist; 2005 Jan; 10(1):63-71. PubMed ID: 15632253
[TBL] [Abstract][Full Text] [Related]
56. An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy.
Montoya VP; Xie J; Williams D; Woodman RC; Wilhelm FE
Support Care Cancer; 2007 Dec; 15(12):1385-92. PubMed ID: 17541653
[TBL] [Abstract][Full Text] [Related]
57. The effect of Epoetin alfa on quality of life in anemic cancer patients.
Cella D; Bron D
Cancer Pract; 1999; 7(4):177-82. PubMed ID: 10687582
[TBL] [Abstract][Full Text] [Related]
58. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.
Welch RS; James RD; Wilkinson PM; Belli F; Cowan RA
Cancer J Sci Am; 1995; 1(4):261-6. PubMed ID: 9166486
[TBL] [Abstract][Full Text] [Related]
59. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease.
Kimel M; Leidy NK; Mannix S; Dixon J
Value Health; 2008; 11(1):57-75. PubMed ID: 18237361
[TBL] [Abstract][Full Text] [Related]
60. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
Witzig TE; Silberstein PT; Loprinzi CL; Sloan JA; Novotny PJ; Mailliard JA; Rowland KM; Alberts SR; Krook JE; Levitt R; Morton RF
J Clin Oncol; 2005 Apr; 23(12):2606-17. PubMed ID: 15452187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
